Niagen Bioscience Inc NAGE
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
Trading Information
- Previous Close Price
- $3.40
- Day Range
- $3.26–3.41
- 52-Week Range
- $3.18–11.29
- Bid/Ask
- $3.26 / $3.31
- Shares Outstanding
- 79.64M
- Market Cap
- $261.23M
- Volume/Avg
- 582,306 / 856,047
Key Statistics
- Price/Earnings (Normalized)
- 15.56
- Price/Sales
- 2.16
- Dividend Yield (Trailing)
- 0.00%
- Dividend Yield (Forward)
- 0.00%
- Total Yield
- 0.10%
Company Profile
Niagen Bioscience Inc is the leader in NAD+ (nicotinamide adenine dinucleotide) science and healthy-aging research. It is dedicated to advancing healthspan through precision science and innovative NAD+-boosting solutions. It is is clinically proven to increase NAD+ levels efficiently and effectively, and is the key ingredient powering our suite of Niagen brands.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Growth
- Total Number of Employees
- 117
- Website
- https://www.niagenbioscience.com
Valuation
|
Metric
|
NAGE
|
|---|---|
Price/Earnings (Normalized) | 15.56 |
Price/Book Value | 3.17 |
Price/Sales | 2.16 |
Price/Cash Flow | 13.73 |
Price/Earnings
NAGE
Financial Strength
|
Metric
|
NAGE
|
|---|---|
Quick Ratio | 3.48 |
Current Ratio | 4.61 |
Interest Coverage | — |
Quick Ratio
NAGE
Profitability
|
Metric
|
NAGE
|
|---|---|
Return on Assets (Normalized) | 14.29% |
Return on Equity (Normalized) | 20.13% |
Return on Invested Capital (Normalized) | 16.63% |
Return on Assets
NAGE
Biotechnology Industry Comparables
|
1-Day Chart
|
Name
|
Price
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|---|
| Vertex Pharmaceuticals Inc
VRTX
| LOCK|xYFQ>P | LOCK|^jhZ | $123B | |||
| Regeneron Pharmaceuticals Inc
REGN
| LOCK|jL#n<%$ | LOCK|mV%@ | $71B | |||
| argenx SE ADR
ARGX
| LOCK|$n^>wM | LOCK|$s | $54B | |||
| BeOne Medicines Ltd ADR
ONC
| LOCK|tx&!vS | LOCK|YPB | $36B | |||
| Alnylam Pharmaceuticals Inc
ALNY
| LOCK|!XPv!rp | LOCK|vnm! | $36B | |||
| Royalty Pharma PLC Class A
RPRX
| LOCK|!Cr!Ls?Y | LOCK|V>y%Q | $26B | |||
| Moderna Inc
MRNA
| LOCK|<@$F$%< | LOCK|R$ | $25B | |||
| Incyte Corp
INCY
| LOCK|%XH@B>> | LOCK|x$^ | $23B | |||
| BioNTech SE ADR
BNTX
| LOCK|b^<RscS | LOCK|!J? | $23B | |||
| BridgeBio Pharma Inc
BBIO
| LOCK|!GK$Ck | LOCK|<@& | $16B |
United States